← Back to all signals
RESEARCH PAPER ANALYSIS

Wrist Vibration Increases Presynaptic Inhibition of the Soleus Muscle During Step Initiation in People With Freezing of Gait and Parkinson's Disease: A Pilot Study.

Pilot study (n=15) found that wrist vibration increased presynaptic inhibition of the soleus and reduced abnormal anticipatory postural adjustments during step initiation in people with Parkinson's disease and freezing of gait.

PMID41895855
JournalThe European journal of neuroscience
Publication Date2026-04-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Pilot study (n=15) found that wrist vibration increased presynaptic inhibition of the soleus and reduced abnormal anticipatory postural adjustments during step initiation in people with Parkinson's disease and freezing of gait.

WHY IT MATTERS

Research significance

Provides proof-of-concept that a non-invasive peripheral vibrotactile stimulus can acutely modulate spinal and supraspinal sensorimotor circuits to reduce freezing-related gait abnormalities, supporting development of wearable symptomatic therapies and further clinical testing.

ABSTRACT

Source abstract

Presynaptic inhibition (PSI) at the spinal cord level is crucial for coordinating postural preparation with step initiation. People with freezing of gait and Parkinson's disease (PD + FOG) show loss of PSI of the soleus muscle during step initiation that is associated with abnormal anticipatory postural adjustments (APA). Here, we hypothesize that increasing PSI of the soleus muscle during step initiation via wrist vibration in PD + FOG would decrease abnormally large APA. Fifteen PD + FOG performed self-initiated steps on a force platform without electrical stimulation and with test or conditioned Hoffman reflexes (H-reflex) to measure PSI of the soleus muscle under three conditions: OFF medication, OFF medication with vibration, and ON medication without vibration. Soleus H-reflexes were recorded during quiet stance (a control task) and when the amplitude of the APA under the same leg exceeded 10%-20% of the mean baseline mediolateral displacement. Vibration consisted of 200-300 Hz applied to the wrist when the ipsilateral leg during APA (same leg where H-reflexes were evoked) was on the ground. PD + FOG showed decreased PSI during APA in OFF and ON medication, but PSI was increased during vibration (p < 0.05). Increased PSI was associated with smaller APA during vibration (p < 0.05). Smaller APAs were associated with lower subjective freezing of gait severity (p < 0.05). These preliminary results show that wrist vibration decreases abnormal APA during step initiation by increasing ipsilateral PSI levels of the soleus muscle. Because PSI is modulated by cortical and brainstem areas related to FOG and APA, proprioceptive drive during vibration may reorganize these brain circuits.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic